| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,990 | 4,155 | 20.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Shattuck Labs stock price target maintained at $18 by Raymond James | 1 | Investing.com | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 05.11. | Shattuck Labs GAAP EPS of -$0.14 misses by $0.04 | 1 | Seeking Alpha | ||
| 05.11. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | XFRA NEW INSTRUMENTS AVAILABLE ON 20.10.2026 | 465 | Xetra Newsboard | The following instruments on XETRA do have their first trading 20.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.10.2026
Aktien
1 CA01451H1047 Alex Metals Corp.
2... ► Artikel lesen | |
| 02.10. | Needham raises Shattuck Labs stock price target on HS trial plans | 2 | Investing.com | ||
| 01.10. | Shattuck Labs plans phase 2 trial for SL-325 in hidradenitis suppurativa | 1 | Investing.com | ||
| 01.10. | Shattuck Labs, Inc.: Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development | 539 | GlobeNewswire (Europe) | - RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first... ► Artikel lesen | |
| 08.09. | Shattuck Labs auf Wells Fargo Konferenz: Strategie fokussiert sich auf DR3-Blockade | 2 | Investing.com Deutsch | ||
| 25.08. | What Shattuck Labs Stock Topped the Market on Monday | 4 | The Motley Fool | ||
| 12.08. | H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion | 1 | Investing.com | ||
| 12.08. | H.C. Wainwright senkt Kursziel für Shattuck Labs wegen Studienerweiterung | 3 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | Shattuck Labs Aktie gibt nach Quartalsbericht nach | 6 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Shattuck Labs GAAP EPS of -$0.12 in-line | 3 | Seeking Alpha | ||
| 11.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 613 | GlobeNewswire (Europe) | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| 25.07. | Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday | 1 | The Motley Fool | ||
| 24.07. | This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday | 1 | Benzinga.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,345 | +0,17 % | Valneva-Aktie über 2,34 Euro: Positive Shigella-Daten geben neuen Schwung | ||
| NOVAVAX | 6,800 | -0,44 % | Novavax fällt nach Quartalszahlen: Warum der Beat die Aktie nicht trägt | ||
| PALATIN TECHNOLOGIES | 4,610 | +0,66 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| VIVOSIM LABS | 0,264 | +1,19 % | VivoSim Labs (VIVS) Stock Jumps 21% After Hours: What's Driving the Move | ||
| OCUGEN | 0,709 | +1,29 % | Ocugen: Lizenzdeal mit Celairis - die Aktie sucht Halt | ||
| VIVORYON THERAPEUTICS | 0,638 | +0,95 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,299 | +3,82 % | 11 Milliarden US-Dollar für drei Fabriken: Warum Novo Nordisk den wahren Biotech-Engpass kauft | ||
| SAREPTA THERAPEUTICS | 12,260 | +0,82 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,500 | -0,03 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| REDHILL BIOPHARMA | 0,281 | +7,66 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| MYRIAD GENETICS | 4,892 | -1,85 % | Myriad Genetics auf Stephens-Konferenz: Verstärkter Fokus auf Onkologie | ||
| MANNKIND | 3,509 | 0,00 % | MannKind auf der Jefferies Global Healthcare Conference: Wachstumstreiber formieren sich - Profitabilität für Q4 2026 im Visier | ||
| ONCO-INNOVATIONS | 0,097 | +2,65 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| NOVOCURE | 9,852 | +0,90 % | Novocure Announces Upcoming Investor Events | Novocure (Nasdaq: NVCR) announced today that management will participate in two upcoming investor events.
Piper Sandler 38th Annual Healthcare Conference, December 1, 2026: Frank Leonard,... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,100 | 0,00 % | Ocular Therapeutix Grants Inducement Stock Awards To Tiffany Howard |